According to Zacks, “Danaher has a decent earnings surprise history, beating estimates thrice, over the trailing four quarters. Of late, the company has been witnessing core revenue growth, margin expansion and earnings improvement, backed by its operating culture – Danaher Business System. Going forward, its diligent acquisition strategies look promising. After the Fortive spin-off on Jul 2, Danaher recently declared the buyout of California-based Cepheid to fortify its presence in the molecular diagnostics market. However, Danaher has been witnessing persistent weakness in key industrial markets, including Latin America and a few European regions, which has put sales under pressure. Also, currency headwinds continue to dent sales and are most likely to mar Danaher’s financials in the near term. Going forward, continual weakness in industrial markets, stiff competition and a stringent regulatory environment may hurt the company's financials.”
A number of other brokerages also recently issued reports on DHR. JPMorgan Chase & Co. reaffirmed a buy rating and set a $105.00 price target on shares of Danaher Corp. in a report on Thursday, June 30th. Citigroup Inc. raised their price target on shares of Danaher Corp. from $102.00 to $104.00 and gave the company a neutral rating in a report on Monday, June 13th. Morgan Stanley reaffirmed a buy rating and set a $86.00 price target on shares of Danaher Corp. in a report on Wednesday, August 31st. Barclays PLC reaffirmed an overweight rating and set a $90.00 price target on shares of Danaher Corp. in a report on Wednesday, July 27th. Finally, Jefferies Group increased their price objective on shares of Danaher Corp. from $92.00 to $93.00 and gave the stock a buy rating in a research note on Tuesday, July 26th. Nine analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Danaher Corp. presently has a consensus rating of Buy and an average price target of $93.98.
Shares of Danaher Corp. (NYSE:DHR) traded up 0.7257% during trading on Thursday, reaching $77.6897. 277,945 shares of the company traded hands. Danaher Corp. has a 12-month low of $61.60 and a 12-month high of $82.64. The stock has a market capitalization of $53.65 billion, a PE ratio of 15.4514 and a beta of 1.13. The firm’s 50-day moving average is $79.24 and its 200-day moving average is $76.34.
Danaher Corp. (NYSE:DHR) last announced its quarterly earnings results on Monday, July 25th. The company reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.03. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.76 billion. Danaher Corp. had a net margin of 15.88% and a return on equity of 13.40%. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.08 EPS. On average, equities analysts predict that Danaher Corp. will post $3.56 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Shareholders of record on Friday, September 30th will be paid a dividend of $0.125 per share. This represents a $0.50 annualized dividend and a yield of 0.65%. The ex-dividend date is Wednesday, September 28th. Danaher Corp.’s payout ratio is 9.94%.
In other news, insider Thomas Patrick Joyce, Jr. sold 45,897 shares of Danaher Corp. stock in a transaction on Monday, August 1st. The stock was sold at an average price of $81.44, for a total transaction of $3,737,851.68. Following the completion of the sale, the insider now directly owns 179,054 shares in the company, valued at $14,582,157.76. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Daniel L. Comas sold 96,446 shares of Danaher Corp. stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $80.88, for a total value of $7,800,552.48. Following the sale, the chief financial officer now owns 215,716 shares of the company’s stock, valued at $17,447,110.08. The disclosure for this sale can be found here. Company insiders own 12.60% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Global X Management Co. LLC increased its stake in Danaher Corp. by 83.4% in the second quarter. Global X Management Co. LLC now owns 1,080 shares of the company’s stock valued at $109,000 after buying an additional 491 shares during the period. Thompson Davis & CO. Inc. increased its stake in Danaher Corp. by 15.3% in the second quarter. Thompson Davis & CO. Inc. now owns 1,284 shares of the company’s stock valued at $130,000 after buying an additional 170 shares during the last quarter. Cribstone Capital Management LLC purchased a new stake in Danaher Corp. during the second quarter valued at $132,000. Monetary Management Group Inc. increased its stake in Danaher Corp. by 366.7% in the first quarter. Monetary Management Group Inc. now owns 1,400 shares of the company’s stock valued at $133,000 after buying an additional 1,100 shares during the last quarter. Finally, Wealthcare Capital Management LLC purchased a new stake in Danaher Corp. during the second quarter valued at $144,000. Institutional investors and hedge funds own 75.74% of the company’s stock.
Danaher Corp. Company Profile
Danaher Corporation designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates in five segments: Test & Measurement; Environmental; Life Sciences & Diagnostics; Dental, and Industrial Technologies. Its Test & Measurement segment offers products, software and services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corp. and related companies with MarketBeat.com's FREE daily email newsletter.